16 May 2017

PureTech Health plc

PureTech Health’s Vedanta Biosciences Granted Three New U.S. Patents for Therapeutics Based on Immune-Modulating Bacterial Consortia

PureTech Health plc ("PureTech", LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that the United States Patent and Trademark Office (USPTO) has issued three new patents to Vedanta Biosciences. The latest issuances further strengthen Vedanta Biosciences’ leading intellectual property position, broadly covering compositions of matter and methods of use for immune-modulating therapeutic products based on microbiome-derived beneficial clostridium bacteria.

Bharatt Chowriria, President and Chief of Business and Strategy at PureTech Health, said: “These new U.S. patents further strengthen Vedanta Biosciences’ leading global IP portfolio, which includes issuances from the European Patent Office, Japan Patent Office, and the United States Patent and Trademark Office, as well as an exclusive, worldwide license from the University of Tokyo. Along with our proprietary technology platform, industry leading intellectual proprietary portfolio, robust pipeline of bacterial consortia-based therapeutics and GMP manufacturing capabilities, we believe Vedanta is well positioned to deliver on the promise of microbiome-based therapeutics.”

The full text of the announcement from Vedanta is as follows:

Vedanta Biosciences Granted Three U.S. Patents Broadly Covering Pharmaceutical Compositions and Methods of Use for Therapeutics Based on Immune-Modulating Bacterial Consortia

CAMBRIDGE, Massachusetts, May 16, 2017— Vedanta Biosciences, pioneering the development of a novel class of therapies for immune and infectious diseases based on rationally designed consortia of bacteria derived from the human microbiome, today announced that the United States Patent and Trademark Office (USPTO) has issued three new patents, 9,642,881, 9,642,882, and 9,649,345. The patents broadly cover compositions of matter and methods of use for therapeutic products based on beneficial clostridium bacteria, further strengthening Vedanta’s leading intellectual property position.

“Our pioneering efforts in the development of therapeutics based on immune-modulating bacterial consortia are continuing to be validated through the issuance of additional composition of matter and method of treatment claims worldwide,” said Bernat Olle, Ph.D., Chief Executive Officer of Vedanta Biosciences. “The expansion of our intellectual property estate and, in particular, these new patents significantly enhance the value proposition for our pipeline and partnered programs.”

The new U.S. patent issuances provide additional support for several programs in Vedanta’s pipeline, including therapies for the treatment of Inflammatory Bowel Disease (IBD) and other autoimmune and infectious diseases. They also build on earlier patent issuances from the USPTO, European Patent Office (EPO), and Japan Patent Office (JPO) to further enhance Vedanta’s global intellectual property portfolio.
About Vedanta Biosciences

Vedanta Biosciences, a subsidiary of PureTech Health (LSE: PRTC; www.puretechhealth.com), is pioneering development of a novel class of therapies for immune and infectious diseases based on rationally designed consortia of bacteria derived from the human microbiome, with clinical trials expected to begin in 2017. Founded by PureTech Health and a group of world-renowned experts in immunology and microbiology, Vedanta Biosciences is a leader in the microbiome field with capabilities to discover, develop and manufacture drugs based on live bacterial consortia. Leveraging its proprietary technology platform and the expertise of its team of scientific co-founders, Vedanta Biosciences has isolated a vast collection of human-associated bacterial strains and characterised how the immune system recognises and responds to these microbes. This work has led to the identification of human commensal bacteria that induce a range of immune responses – including induction of regulatory T cells and Th17 cells, among others – as well as the characterisation of novel molecular mechanisms of microbial-host communication. These advances have been published in leading peer-reviewed journals including Science, Nature (multiple), Cell and Nature Immunology. Vedanta Biosciences has harnessed these biological insights as well as data from clinical translational collaborations to generate a pipeline of programs in development for infectious disease, autoimmune disease, inflammation and immune-oncology. The clinical potential of therapeutic manipulation of the microbiome has been validated by multiple randomised, controlled trials in infectious disease and inflammatory bowel disease. Vedanta Biosciences has a leading global intellectual property portfolio in the microbiome field with patents issued by the European Patent Office (EPO), Japan Patent Office (JPO) and the United States Patent and Trademark Office (USPTO), and through patent families exclusively licensed worldwide to Vedanta under an agreement with the University of Tokyo.

Vedanta Biosciences’ scientific co-founders have pioneered the fields of innate immunity, Th17 and regulatory T cell biology, and include Dr. Ruslan Medzhitov (Professor of Immunobiology at Yale), Dr. Alexander Rudensky (tri-institutional Professor at the Memorial Sloan-Kettering Institute, the Rockefeller University and Cornell University), Dr. Dan Littman (Professor of Molecular Immunology at NYU), Dr. Brett Finlay (Professor at the University of British Columbia) and Dr. Kenya Honda (Professor, School of Medicine, Keio University). Vedanta is backed by PureTech Health, Seventure, Invesco Asset Management, and Rock Springs Capital.

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is an advanced, clinical-stage biopharmaceutical company developing novel medicines that modulate the adaptive human systems. PureTech’s therapies target the dysfunctions in the immune, nervous, and gastro-intestinal systems by addressing the underlying pathophysiology of disease from a systems perspective rather than through a single receptor or pathway. The Company is advancing a rich pipeline that includes multiple human proof-of-concept studies and pivotal or registration studies expected to read out over the next 12-18 months. PureTech Health’s growing research and development pipeline has been developed in collaboration with some of the world’s leading scientific experts, who along with PureTech’s experienced team and a stellar Board identify, analyse and advance very selectively the opportunities the Company believes hold the most promise for patients. This experienced and engaged team places PureTech Health at the forefront of ground-breaking science and technological innovation and leads
the Company between and beyond existing disciplines. For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

**Forward Looking Statement**

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company’s future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

**Contact:**

**PureTech Health**
Allison Mead  
+1 617 651 3156  
amead@puretechhealth.com

**FTI Consulting**
Ben Atwell, Matthew Cole,  
Rob Winder  
+44 (0) 20 3727 1000